Black Diamond Therapeutics
BDTX
91 hedge funds and large institutions have $147M invested in Black Diamond Therapeutics in 2025 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 28 increasing their positions, 23 reducing their positions, and 24 closing their positions.
2,547% more call options, than puts
Call options by funds: $450K | Put options by funds: $17K
53% more capital invested
Capital invested by funds: $95.8M → $147M (+$51.2M)
22% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 23
0.2% more ownership
Funds ownership: 67.91% → 68.11% (+0.2%)
3% less funds holding
Funds holding: 94 → 91 (-3)
13% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.22M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$1.64M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.41M |
| 4 |
Renaissance Technologies
New York
|
+$1.26M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$985K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$6.78M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$804K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$571K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$479K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$459K |
BDTX Hedge Fund Activity: Q3 2025 in Review
91 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q3 2025, worth a combined $147M — up 53% from $95.8M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of BDTX and 21 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 28 added.
The largest buyer was Arrowstreet Capital, adding an estimated $2.22M. The largest seller was Bellevue Group, exiting entirely with an estimated $6.78M sold.
- 91 institutional investors held Black Diamond Therapeutics (BDTX) as of Q3 2025, down from 94 in Q2 2025.
- Funds reported $147M of Black Diamond Therapeutics stock for Q3 2025, up 53% quarter-over-quarter.
- 21 funds opened new Black Diamond Therapeutics positions in Q3 2025 and 24 closed out, a net change of -3 holders.
- The largest Black Diamond Therapeutics buyer in Q3 2025 was Arrowstreet Capital, an estimated $2.22M added.
- The largest Black Diamond Therapeutics seller in Q3 2025 was Bellevue Group, an estimated $6.78M sold.
Based on aggregated 13F filings for Q3 2025.